Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates

Simply Wall St.04-22

Ocular Therapeutix (OCUL) has caught investor attention after recent share price swings, with the stock closing at US$9.32. The company focuses on bioresorbable hydrogel therapies for retinal diseases...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629802889?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-04-22 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629802889","market":"nz","top_or_hot":-1,"title":"Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates","media":"Simply Wall St.","content":"<div>\n<p>Ocular Therapeutix (OCUL) has caught investor attention after recent share price swings, with the stock closing at US$9.32. The company focuses on bioresorbable hydrogel therapies for retinal diseases...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/assessing-ocular-therapeutix-ocul-valuation-as-axpaxli-prosp\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-22 22:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/assessing-ocular-therapeutix-ocul-valuation-as-axpaxli-prosp><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocular Therapeutix (OCUL) has caught investor attention after recent share price swings, with the stock closing at US$9.32. The company focuses on bioresorbable hydrogel therapies for retinal diseases...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/assessing-ocular-therapeutix-ocul-valuation-as-axpaxli-prosp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCUL","symbol_name":"Ocular Therapeutix","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/assessing-ocular-therapeutix-ocul-valuation-as-axpaxli-prosp","article_id":"2629802889","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/assessing-ocular-therapeutix-ocul-valuation-as-axpaxli-prosp","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629802889","pubTimestamp":1776867017,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ocular Therapeutix (OCUL) has caught investor attention after recent share price swings, with the stock closing at US$9.32. The company focuses on bioresorbable hydrogel therapies for retinal diseases and other eye conditions.\nSee our latest analysis for Ocular Therapeutix.\nRecent trading has been choppy, with a 1 day share price return of 2.1% decline, a 7 day gain of 6.39%, and a 30 day share price return of 13.94%. Even so, the 90 day share price return of 18.39% decline and year to date...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCUL":"Ocular Therapeutix","BK4007":"制药"},"translate_title":"评估Ocular Therapeutix(OCUL)估值，因为AXPAXLI前景与公允价值估计存在巨大差距","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUL":1.5},"content_text":"Ocular Therapeutix (OCUL) has caught investor attention after recent share price swings, with the stock closing at US$9.32. The company focuses on bioresorbable hydrogel therapies for retinal diseases and other eye conditions. See our latest analysis for Ocular Therapeutix. Recent trading has been choppy, with a 1 day share price return of 2.1% decline, a 7 day gain of 6.39%, and a 30 day share price return of 13.94%. Even so, the 90 day share price return of 18.39% decline and year to date share price return of 21.15% decline contrast with a 1 year total shareholder return of 17.83% and a 3 year total shareholder return of 57.97%, suggesting that recent momentum has cooled after a stronger multi year run. If you are comparing Ocular Therapeutix with other high growth opportunities in related areas, it may be helpful to review a curated set of healthcare focused AI names via 34 healthcare AI stocks With Ocular Therapeutix trading at US$9.32 against an analyst price target of US$26.00 and an intrinsic value estimate that implies a sizable discount, the key question is whether this gap signals a genuine opportunity or if the market is already factoring in future growth. AdvertisementMost Popular Narrative: 64.2% Undervalued At a last close of $9.32 against a most followed fair value estimate of $26.00, the narrative frames Ocular Therapeutix as heavily discounted and firmly tied to the AXPAXLI program.  The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.  Read the complete narrative. Curious what supports that fair value gap? The narrative leans on rapid revenue expansion, a sharp shift in margins, and a future earnings multiple that stands well above typical pharma names. Result: Fair Value of $26 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside story still leans heavily on AXPAXLI clearing key Phase 3 and regulatory hurdles, and on the company managing cash needs without more dilution than expected. Find out about the key risks to this Ocular Therapeutix narrative. Another Way to Look at Value The earlier view relies heavily on an earnings-based fair value of US$26. In contrast, our DCF model presents a more aggressive perspective, with a future cash flow value of US$93.63 per share, or about 90% above the current US$9.32 price. Is this a significant opportunity, or simply very optimistic math? Look into how the SWS DCF model arrives at its fair value. OCUL Discounted Cash Flow as at Apr 2026Next Steps The mix of risks and rewards around Ocular Therapeutix is clear. Now is the time to review the details and decide where you stand based on the 2 key rewards and 4 important warning signs Ready to uncover more investment ideas? If you stop at just one company, you risk missing other compelling setups that fit your goals, so widen your search now using focused stock screeners.  Target potential mispricing by reviewing companies that appear cheap on quality and fundamentals through the 58 high quality undervalued stocks. Prioritise resilience by scanning for businesses with stronger financial footing using the solid balance sheet and fundamentals stocks screener (41 results). Spot opportunities others might miss by filtering for under followed but financially sound names with the screener containing 23 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629802889","isCrawlerRequest":true}